Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316246 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL33584 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1369560 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3130561 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL4126076 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL3128140 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ammonia Solution, Strong SCHEMBL16720911 | 0.98 | LMNA (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8675811 | 0.98 | TDP1 (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Acetic Acid SCHEMBL680584 | 0.94 | PDE4A (0.44) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL616881 | 0.94 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2024-09-12 | — | — | US | claimed |
| EP-4294447-A1 | POLYSACCHARIDE COMPLEX | Acaryon GmbH (DE) | 2023-12-27 | — | — | EP | claimed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2022175390-A1 | POLYSACCHARIDE COMPLEX | ACARYON GMBH (DE) | 2022-08-25 | — | — | WO | claimed |
| CN-108794547-B | Preparation method of 3-O-carbamyl mannose donor derivative, bleomycin disaccharide and precursor thereof | 广州中医药大学(广州中医药研究院) | 2021-08-10 | — | — | CN | claimed |
| CN-108948106-B | Preparation method of 2-hydroxy gulose receptor derivative, bleomycin disaccharide and precursor thereof | 广州中医药大学(广州中医药研究院) | 2021-08-10 | — | — | CN | claimed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | claimed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | claimed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | claimed |
| US-9114176-B2 | Exogenously triggered controlled release materials and uses thereof | SMARTCELLS, INC. (US) | 2015-08-25 | — | — | US | claimed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010107519-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088268-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| EP-2150620-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES, AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES | Libragen (FR) | 2010-02-10 | — | — | EP | claimed |
| WO-2008142155-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES | LIBRAGEN (FR) | 2008-11-27 | — | — | WO | claimed |
| EP-1995323-A1 | Method for preparing C-6 phosphorylated D-aldohexoses and C-6 phosphorylated D-aldohexose derivatives | Libragen (FR) | 2008-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301178-A1 | POLYSACCHARIDE COMPLEX | SGMS1, UGCG, SGMS2 | LMNA 1448/4885L3MBTL1 3218/4885TDP1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.